Compare Neurocrine Biosciences Inc (NBIX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Williams Companies Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.37 (market cap $14.36B), while Williams Companies Inc trades at $72.85 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 6.2× Neurocrine Biosciences Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Williams Companies Inc for 58 Days on average.
| NBIX | WMB | |
|---|---|---|
Market Cap | $14.36B | $88.48B |
Volume | 1,237,180 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $185.50 | $79.40 |
52-Week Low | $123.10 | $56.51 |
Typical Hold Time | 23 Days | 58 Days |
Enterprise Value | $14.37B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Williams Companies (WMB) trades at $71.46, down 1.28% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with 25.18% net income margin and 24.02% ROE, though recent earnings have been mixed with two misses and one beat. Analyst consensus is strongly bullish with 79% buy ratings and an $87.27 price target, representing 22% upside. Recent news highlights WMB's positioning to benefit from AI-driven natural gas demand growth.
WMB offers compelling value with strong cash flow generation and dividend growth potential, though investors face risks from energy market volatility and high debt levels. The company's fee-based revenue model provides stability, while strategic acquisitions like Momentum Midstream enhance growth prospects. Current valuation at 28.82 P/E appears reasonable given the growth trajectory and defensive characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
